Market News & Trends
Particle Sciences Granted Patent on Self-Sterilizing Medical Devices
Particle Sciences Inc. (PSI), a leading pharmaceutical CRO, has received Notice of Allowance for a method of sterilizing medical devices. The patent covers the notion…
Puma Biotechnology Announces Licensing Agreement With Pfizer
Puma Biotechnology, Inc., a development-stage biopharmaceutical company, recently announced an agreement with Pfizer to license the worldwide commercial rights to neratinib, a potent, irreversible tyrosine…
Unilife Wins Supply Contract With Nation's Largest Healthcare Alliance
Unilife Corporation recently announced it has been awarded a 2-year contract by Premier Purchasing Partners, L.P., the group purchasing enterprise of the Premier healthcare alliance,…
Zosano Pharma & Asahi Kasei Pharma Enter Agreement for Transdermal Patch for Up to $132.5 Million
Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation (AKP) recently announced they have entered into a long-term strategic collaboration for the development, commercialization, and supply…
CoreRx Adds Additional Capabilities With New Tablet Press
CoreRx, a leader in early drug contract development, has expanded manufacturing capabilities to include the OYSTAR Manesty FLEXITAB, a fully automated, single station tablet press…
Novozymes to Supply Recombumin for Type 2 Diabetes Drug
Novozymes to Supply Recombumin for Type 2 Diabetes Drug Novozymes Biopharma, part of Novozymes A/S, recently announced it has concluded an exclusive supply agreement with…
Silence Therapeutics Signs siRNA Delivery Collaboration
Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, recently announced it has entered into an agreement with one of the world's leading global…
Talon Therapeutics' NDA Accepted for Filing by US FDA Under Subpart H
Talon Therapeutics, Inc. recently announced its NDA seeking accelerated approval of Marqibo (vincristine sulfate liposomes injection) has been accepted for filing by the FDA. Marqibo…
UPM Pharmaceuticals to Add Low Humidity, OEB 4 & Specialized Xcelodose Manufacturing Capability
UPM Pharmaceuticals recently announced it will expand its existing manufacturing capacity, including an OEB 4 processing room, a low humidity processing suite, and a unique…
10/4/2011
Talon Therapeutics' NDA Accepted for Filing by US FDA Under Subpart H Talon Therapeutics, Inc. recently announced its NDA seeking accelerated approval of Marqibo (vincristine…
Boehringer Ingelheim Expands its Business With Biosimilars
As part of its corporate strategy, Boehringer Ingelheim recently announced it will establish a new separate business for the development and commercialization of its own…
9/27/2011
Thermo Fisher Scientific Introduces New Imaging ATR Accessory Thermo Fisher Scientific Inc., a world leader in serving science, recently announced the launch of a new…
Ambrx & BMS Announce $24-Million Collaboration for Novel Biologics Programs
Ambrx, Inc. and Bristol-Myers Squibb Company recently announced a collaboration under which Bristol-Myers Squibb will receive exclusive worldwide rights to research, develop, and commercialize biologics…
First Application of Haselmeier's Injection Pen Launched
Haselmeier recently announced that the first application of its Axis-D pen platform has been launched. Commissioned by its client Merck Serono, a division of Merck…
Kythera Biopharmaceuticals Raises $37.4-Million Financing
KYTHERA Biopharmaceuticals, Inc. recently announced the closing of a $37.4-million Series D financing. The round featured significant new investments as well as participation from all…
Loxbridge & Dr. Kary Mullis Announce the Formation of Altermune Technologies
Dr. Kary Mullis, the Nobel Prize-winning inventor of the Polymerase Chain Reaction (PCR), the cornerstone of much of today's DNA science, has entered a new…
Thermo Fisher Scientific Introduces New Imaging ATR Accessory
Thermo Fisher Scientific Inc., a world leader in serving science, recently announced the launch of a new imaging attenuated total reflectance (ATR) accessory offering enhanced…
Unigene Divests Non-Core Asset & Focuses Resources on High Valuation Drug Development & Peptide Delivery
Unigene Laboratories, Inc. recently announced it has divested its non-core asset, Site Directed Bone Growth (SDBG) by assigning seven patent applications to Kieran Murphy, LLC.…
KAI Pharmaceuticals Inks $13-Million Development Deal With Ono Pharmaceutical
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, recently announced the signing of an agreement with Ono Pharmaceutical Co., Ltd. for the…
NanoSmart Begins Development of New Drug Delivery Platform for Cancer
NanoSmart Pharmaceuticals, Inc., a biopharmaceutical corporation developing novel cancer pharmaceuticals, has moved into its new corporate facility located in Laguna Hills, CA. The facility provides…
